Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now official registry

Stage IV Bladder Cancer AJCC v8 clinical trials

5 of 8 indexed Stage IV Bladder Cancer AJCC v8 trials are currently recruiting.

8 US clinical trials · 5 currently recruiting

Stage IV Bladder Cancer AJCC v8 is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

The research picture

Stage IV Bladder Cancer AJCC v8 has 8 registered US clinical trials, 5 of them open to new participants right now, about 63% of the total.

5
recruiting participants now
63%
of trials open to enrollment
2
in Phase 3–4 (later-stage)
3
top sponsor: National Cancer Institute (NCI)
Phase 11Phase 24Phase 31Phase 41

Active & Recent Trials

8 total, page 1 of 1

RECRUITING NA 160 participants

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Roswell Park Cancer Institute

NCT06414317

RECRUITING Phase 4 75 participants

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

NCT06764095

RECRUITING Phase 2 64 participants

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Northwestern University

NCT06630416

RECRUITING Phase 2 60 participants

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

NCT03375307

RECRUITING Phase 2 25 participants

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

NCT05756569

ACTIVE NOT RECRUITING Phase 3 184 participants

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

NCT04579224

ACTIVE NOT RECRUITING Phase 1 30 participants

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

National Cancer Institute (NCI)

NCT03854474

ACTIVE NOT RECRUITING Phase 2 13 participants

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Jonsson Comprehensive Cancer Center

NCT03601455

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 1
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Stage IV Bladder Cancer AJCC v8 Trial Landscape

8 indexed Stage IV Bladder Cancer AJCC v8 studies · 5 recruiting (63%).

Phase mix: 2 late (III/IV) vs 5 early (I/II).

Top sponsor: National Cancer Institute (NCI) (3 trials), 5 others listed. 8 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Stage IV Bladder Cancer AJCC v8?

PlainTrial tracks 8 US clinical trials for Stage IV Bladder Cancer AJCC v8, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Stage IV Bladder Cancer AJCC v8?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.